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Abstract  
 
The phosphatidylinositide 3-kinases (PI3K) and mammalian target of rapamycin-1 (mTOR1) are 
two key targets for anti-cancer therapy. Predicting the response of the PI3K/AKT/mTOR1 
signalling pathway to targeted therapy is made difficult because of network complexities. 
Systems biology models can help explore those complexities but the value of such models is 
dependent on accurate parameterisation. Motivated by a need to increase accuracy in kinetic 
parameter estimation, and therefore the predictive power of the model, we present a 
framework to integrate kinetic data from enzyme assays into a unified enzyme kinetic model. 
We present exemplar kinetic models of PI3K and mTOR1, calibrated on in vitro enzyme data 
and founded on Michaelis-Menten (MM) approximation. We describe the effects of an 
allosteric mTOR1 inhibitor (Rapamycin) and ATP-competitive inhibitors (BEZ2235 and 
LY294002) that show dual inhibition of mTOR1 and PI3K. We also model the kinetics of 
phosphatase and tensin homolog (PTEN), which modulates sensitivity of the PI3K/AKT/mTOR1 
pathway to these drugs. Model validation with independent data sets allows investigation of 
enzyme function and drug dose dependencies in a wide range of experimental conditions. 
Modelling of the mTOR1 kinetics showed that Rapamycin has an IC50 independent of ATP 
concentration and that it is a selective inhibitor of mTOR1 substrates S6K1 and 4EBP1: it 
retains 40% of mTOR1 activity relative to 4EBP1 phosphorylation and inhibits completely S6K1 
activity. For the dual ATP-competitive inhibitors of mTOR1 and PI3K, LY294002 and BEZ235, 
we derived the dependence of the IC50 on ATP concentration that allows prediction of the IC50 
at different ATP concentrations in enzyme and cellular assays. Comparison of the drug 
effectiveness in enzyme and cellular assays showed that some features of these drugs arise 
from signalling modulation beyond the on-target action and MM approximation and require a 
systems-level consideration of the whole PI3K/PTEN/AKT/mTOR1 network in order to 
understand mechanisms of drug sensitivity and resistance in different cancer cell lines. We 
suggest that using these models in systems biology investigation of the PI3K/AKT/mTOR1 
signalling in cancer cells can bridge the gap between direct drug target action and the 
therapeutic response to these drugs and their combinations.  
 
Keywords: kinetic modelling; PI3K; mTOR1; PTEN; Rapamycin; BEZ235  
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1. Introduction 
 
The kinases, the mammalian target of Rapamycin (mTOR1/2), and phosphoinositide-3 
kinase (PI3K) are central hubs in the regulation of anti-apoptotic and proliferation signalling in 
the PI3K/PTEN/AKT/mTOR1/S6K1 network (Cully et al., 2006; Laplante and Sabatini, 2012). 
Given this regulatory role, they are considered pivotal targets in cancer drug therapy (Zoncu et 
al., 2011). The fundamental goal in targeted therapy drug development is high therapeutic 
efficacy, and this efficacy is characterised not only by inhibition of the targeted protein but 
also by the response of the whole signalling network to on-target inhibition.  
Predicting the response of the PI3K/PTEN/AKT/mTOR1/S6K1 signalling network to 
targeted therapy is made difficult because of pathway complexities. These complexities 
include multiple extra- and intra-cellular stimuli, extensive crosstalk with other signalling 
pathways, multiple feedforwards and feedbacks within pathways, and aberrations in different 
proteins (Chandarlapaty, 2012). These complexities and protein mutations within the pathway 
combine in ways that can induce pathway hyperactivation in cancer cells and lead to de novo 
and acquired drug resistance in different cancers (Wang et al., 2009). 
The schematic in Fig. 1 shows the pathways involved in the activation of the 
PI3K/PTEN/AKT/mTOR1/S6K1 network by receptor tyrosine kinase (RTK) signalling. Upstream 
stimulation of the network results in recruitment and phosphorylation of PI3K, which then 
phosphorylates phosphatidylinositol 4,5 bisphosphate (PIP2) to phosphatidylinositol 3,4,4-
triphosphate (PIP3). The second lipid messenger PIP3 in turn recruits downstream proteins to 
the plasma membrane and this leads to phosphorylation of AKT and PDK1 kinases. 
Phosphatase and tensin homolog deleted on chromosome ten (PTEN) dephosphorylates PIP3 
into PIP2. A normal function of PI3 kinase and phosphatase PTEN strictly control the response 
of AKT signalling to RTK stimuli (Goltsov et al., 2012). The most common aberrations in the 
PI3K/PTEN cycle, observed in 80% of cancers, are loss of PTEN and/or PIK3CA mutations that 
cause activation of the PI3K/PTEN/AKT/mTOR1/S6K1 signalling network independently of RTK 
signals, which can lead to tumourigenesis and drug resistance (Nik-Zainal et al., 2016; Stemke-
Hale et al., 2008).  
mTOR acts as a key downstream integrator of PI3K/PTEN/AKT signalling and the 
serine/threonine protein kinase assembles into two complexes, mTOR1 and mTOR2: mTOR1 is 
a major regulator of cap-dependent translation and elongation via phosphorylation of 4EBP1 
and S6K1 respectively (Siddiqui and Sonenberg, 2015); mTOR2 phosphorylates AKT(Ser437) 
(Cully et al., 2006). Besides kinase catalytic domains, mTOR has several domains (FAT, HEAT, 
FRB) acting as structural scaffolding for different subunits of the mTOR1 and mTOR2 
complexes (Raptor, Rictor, PRAS40, and mSLT8) which regulate its binding to 
substrate/activator, catalytic activity and localisation (Yang et al., 2013). Phosphorylation of 
S6K1 at multiple phospho-sites by both mTOR1 and PDK1 (Phosphoinositide-dependent 
kinase-1) forms feedforward and feedback loops in the PI3K/PTEN/AKT/mTOR1/S6K1 pathway 
(Fig. 1). These feedback loops, together with crosstalk with the MAPK pathway and mTOR1 
autoregulation through protein-protein interactions, mean that drug action must account for 
system-scale properties. That is, the response of the output signal is defined by properties of 
the whole signalling network, since it is the whole network that modulates functioning of the 
specific drug targeted proteins.  
Multiple drugs targeting this pathway are in clinical practice or preclinical development 
(Kalachand et al., 2011; Markman et al., 2010), and here we focus on Rapamycin and BEZ235 
(Mita et al., 2016). We also consider LY294002 because of its common use in studies of the 
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response of PI3K/AKT pathway to inhibition in different cancer cell lines (Vlahos et al., 1994; 
Walker et al., 2000). Rapamycin is a mTOR-targeting molecule isolated from bacteria and used 
as an antifungal and immunosuppressive drug (Laplante and Sabatini, 2012; Wang et al., 
2009). In preclinical studies, Rapamycin has shown anti-tumour effects against various tumour 
types including breast cancer, glioblastoma, rhabdomyosarcoma by controlling cell survival, 
angiogenesis and proliferation (Laplante and Sabatini, 2012; Wang et al., 2009). Temsirolimus, 
a rapamycin rapalog, was approved to treat progressive renal cell carcinoma in the clinic 
(Hudes et al., 2007). Although Rapamycin rapalogs have shown promising antitumour effects 
in preclinical studies, most of the clinical trial outcomes were disappointing. The existence of 
several feedback loops in the PI3K/AKT/mTOR pathway may have played an important role in 
the limitation of Rapamycin in addition to its inadequacy in blocking mTORC2 (Harrington et 
al., 2004; Jacinto et al., 2004; Yu et al., 2011). 
Both PI3K and mTOR belong to the PI3K-related kinase (PIKK) family, and so both might  
be inhibited by the same ATP competitive inhibitors, resulting in dual activity against both 
targets. BEZ235 is a potent PI3K/mTOR dual inhibitor that blocks both class I PI3K and 
mTOR1/2 through competition for the ATP-binding sites of these enzymes (Maira et al., 2008). 
In vitro and in vivo studies have shown its high anti-proliferative activities in neoplastic cells as 
well as a reduction in the phosphorylation level of AKT and its downstream proteins (Jebahi et 
al., 2014; Maira et al., 2008; Serra et al., 2008). BEZ235 is currently in phase 1/2 clinical trials 
and is being tested against a number of solid tumours including breast, endometrial, renal and 
pancreatic tumours. Results show good dose toleration but limited clinical response as a 
monotherapy or in combination with other drugs (Bendell et al., 2015).  
LY294002 is an ATP competitive inhibitor of PI3K (p110/) and, although it is not in 
clinical practice due its toxicity, it is widely used in numerous cell line studies to inhibit the 
PI3K/AKT pathway. Studies have revealed that LY294002 is not specifically selective for PI3K 
and can have off-target effects, and mTOR is among those off-targets impacted by LY294002 
(DNA-dependent kinase (DNA- K), casein kinase  (2CK2), GSK3) (Gharbi et al., 2007; Toral-
Barza et al., 2005). Accordingly, some of these off-target effects of LY294002 relate to the 
PI3K/AKT/mTOR pathway and might contribute to the overall inhibition effect observed upon 
cell treatment. Toral-Barza et al. (Toral-Barza et al., 2005) showed that LY294002 is a 
PI3K/mTOR dual inhibitor that blocks PI3K and mTOR kinase through an ATP-competitive 
mechanism. 
Studies on the PI3K/PTEN/AKT/mTOR1/S6K1 pathway reveal clear discrepancies 
among drug efficacy readouts at the target, pathway and cellular levels for different cancer 
cell lines (Hassan et al., 2014; Santiskulvong et al., 2011; Shoji et al., 2012). These observed 
discrepancies are likely due to a mix of the complexity of the signalling network and its 
mutations together with fundamental differences in enzyme kinetics in various cellular 
environments. In particular, intracellular conditions in cancer cells may be significantly 
different to experimental conditions in enzymatic assays, e.g. substrate and cofactor 
concentrations (Acker and Auld, 2014). To inform the comparison of drug efficacies obtained 
in enzymatic and cellular assays, and to combine the data derived from these assays, we need 
data on protein and inhibition kinetics in different cancer cells in different conditions. In 
general, key intracellular conditions cannot be modelled in enzymatic assays but these can be 
modelled in in silico experiments using enzyme kinetic models that describe enzyme and 
inhibitor properties in a wide region of environmental conditions. 
This paper provides a systems biology framework to integrate kinetic data from 
enzymatic and cellular assays into a unified kinetic model. Fig. 2 shows a schematic of this 
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framework, where data describing enzyme activity following drug action may be combined 
with enzyme kinetic data to predict the IC50 for drugs in different cellular conditions.  
Integration of various kinds of experimental data is motivated by a need to increase accuracy 
in kinetic parameter estimation and therefore the predictive power of the systems biology 
models. Accurate estimations of enzyme kinetic parameters are needed to ‘bridge the gaps in 
systems biology’ (Cvijovic et al., 2014) by reducing model uncertainty. A well calibrated model 
can be used to help explain the observed discrepancies of enzyme function and drug effects in 
different experimental conditions, in different cellular environment as well as in analysis of 
enzyme mutation effects of drug action in various cellular lines. 
Previous models of enzyme kinetics that are based on detailed kinetic mechanisms and 
integration of a wide range of  in vitro experimental data can be found e.g. for Rho GTPases 
(Goryachev and Pokhilko, 2006), the adenine nucleotide translocase (Metelkin et al., 2009), 
and S6K1 protein kinase (Keshwani and Harris, 2008). We extend these approaches by 
demonstrating the incorporation of experimental data that characterises enzymatic response 
to drug action to inform model construction. Here, as an exemplar use of this framework we 
present kinetic models of purified enzymes PI3K, mTOR1 and PTEN that describe their catalysis 
mechanisms. We apply these models to investigate the effects of allosteric (Rapamycin) and 
ATP-competitive (BEZ235, L294002) inhibitors of mTOR1 and PI3K. We use Michaelis-Menten 
(MM) approximation in our model formulation combined with in vitro protein assay data on 
enzyme kinetics to calibrate and then validate the models. In line with the increasing 
publications devoted to the expansion of MM approximation and its application in metabolic 
and signalling network investigation  (Cornish-Bowden, 2013; Schnell, 2014; Tummler et al., 
2014) we test whether the kinetics of these kinases and phosphatase can be described in MM 
approximation and reproduce such indicators as kinetic curves, inhibition constants, dose 
dependencies and IC50 values. We compare drug activities in purified protein assays and those 
in cancer cell populations in order to determine those drug properties which can be described 
by MM kinetics and those properties that lie beyond this approximation and depend on an 
understanding of the whole signalling network response. We also discuss an application of this 
comparative analysis to translation of in vitro data on drug activity to therapeutic drug 
efficacy.  
 
2. Methods 
 
The schematic of our approach is shown in Fig. 2. For model development, calibration 
and validation we used two types of experimental data: dependencies of enzyme activity on 
substrate concentrations measured in the absence and presence of drugs and dose 
dependencies of enzyme inhibition on drug concentrations. The developed approach allows us 
to integrate kinetic experimental data obtained under different experimental conditions. 
Integrating data increases model reliability and accuracy with respect to kinetic parameter 
estimation because of an increase in the set of experimental points used in that estimation 
over separate experimental data sets (Cornish-Bowden, 2014). Moreover, we also make use of 
molecular structural data on enzyme-substrate and enzyme-drug complexes to support model 
formulation. Specifically, involvement of these structural data can serve to discriminate 
among different candidate mechanisms of drug action, e.g. inhibition of enzyme activity or 
substrate affinity. We can validate the model on independent data sets and then this validated 
model may be used to investigate enzyme functions in experimental conditions beyond those 
used in its construction.  
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Fitting of experimental data was carried out using the constrained nonlinear 
optimization method running Matlab (MathWorks Inc.). Standard errors and confident 
intervals of the kinetic parameters obtained in fitting were estimated using the bootstrap 
method (Draper and Smith, 2014; Efron and Tibshirani, 1994). In the bootstrap procedure we 
used a resampling process for the n residues  
               
where      and       are vectors of the experimental data and the best fitted model results; 
e is a vector of the residues of dimension N corresponding to a number of experimental 
points. Then we generate M bootstrap residues vector   
  where each element is chosen from 
the elements of the residue vector   with probability 1/n. At the next step of the bootstrap 
procedure, the model is fitted against bootstrap samples   
      
         
  
to define the estimates of M samples of kinetics parameters    .  
As an estimate of kinetic parameter    we use the median of M bootstrap samples for 
parameter    obtained in the fitting procedure. As a bootstrap confidence interval (CI) we 
calculate the percentile confidence interval                , where        and      are 2.5th 
and 97.5 percentile of the distribution of    obtained  in the bootstrap process (Efron and 
Tibshirani, 1994). We compared these estimates of parameters    with the mean values     of 
M bootstrap samples and the 95% standard normal confidence interval                    
          where     is the estimate of standard error of the bootstrap mean of kinetic 
parameter     
               
 
 
   
       
   
  
 
2.1 Kinetic model of mTOR1 complex and its inhibition 
 
We developed a kinetic model of the catalytic cycle of the mTOR1 complex that 
catalyses phosphorylation of S6K1 and 4EBP1 kinases (Fig. 3). The model was developed in 
accordance with the framework of a two substrate random bi-bi mechanism of enzymatic 
reaction using an approximation of fast binding of substrates (ATP, S6K1 and 4EBP1) (Cornish-
Bowden, 2004). In the catalytic cycle we considered the allosteric inhibitor of mTOR1, 
Rapamycin (Rap), and two ATP-competitive inhibitors, BEZ235 and LY294002. According to 
experimental data, Rapamycin binds with low affinity (26 μM (Banaszynski et al., 2005)) to the 
FRB domain of mTOR (FKBP-rapamycin binding domain) and its binding becomes much 
stronger in the presence of FKBP12 protein (FK506-binding protein 12). The high affinity of 
Rapamycin with FKBP12 protein (0.2 nM (Banaszynski et al., 2005)) leads to Rapamycin 
binding to mTOR1 through the formation of the trimeric complex FKBP12-Rapamycin-FRB with 
dissociation constant 12±0.8 nM (Banaszynski et al., 2005). In the catalytic cycle we included 
the mTOR1 binding reaction in the absence and presence of the FKBP12 with dissociation 
constant Kd,Rap1 and  Kd,Rap2 respectively. Considering these data, and other experimental data 
on inhibition of S6K1 and 4EBP1 phosphorylation by mTOR1 (Choo et al., 2008; Tao et al., 
2010; Toral-Barza et al., 2005), we assumed that mTOR1 binding to Rapamycin or Rapamycin-
FKBP complexes retains its residual catalytic activity  relating to 4EBP1 and causes its full 
suppression relating to S6K1 (see Fig. 3). 
 In line with the developed catalytic cycle (Fig. 3) we derived rate equations of  the 
phosphorylation of 4EBP1, V4EBP1, and S6K1, VS6K1, according to a random bi-bi mechanism 
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approximation for a two substrate reaction (Cornish-Bowden, 2004; Demin and Goryanin, 
2008) as follows:    
 
       
                      
                    
             
 
(1) 
      
                    
                   
  (2) 
where  
         
   
     
 
  
     
 
   
     
    
     
        
 
    
       
        
 
  
   
      
 
        
      
  
 
Here Kd,i are the dissociation constants of substrates 4EBP1 and S6K1 and inhibitors 
Rapamycin (Rap), BEZ235 (BEZ), and LY294002 (LY); k4EBP1 and kS6K1 are catalytic rates. η4EBP1=     
k4EBP1,Rap/k4EBP1 is the inhibition coefficient of mTOR reaction rate for 4EBP1 phosphorylation 
by Rapamycin which is equal to the ratio of residual catalytic activity of mTOR1-Rapamycin 
complex, k4EBP1,Rap, to the catalytic activity of mTOR1, k4EBP1. Equations (1) and (2) thus 
describe the competitive kinetics of the two substrates 4EBP1 and S6K1 for enzyme mTOR1, 
and this corresponds to the two-substrate reactions catalysed by mTOR1 in cells. 
 
2.2 Kinetic model of PI3K and its inhibition by LY294002 and BEZ235 
 
A model of the catalytic cycle of PI3K catalysing the phosphorylation of PIP2 was 
developed using the same MM approximation as in the case of mTOR1 modelling (Fig. 4). In 
the catalytic cycle we considered the same ATP competitive inhibitors, LY294002 and BEZ235. 
In line with  the PI3K catalytic cycle (Fig. 4), we derived rate equations of PIP2 
phosphorylation, V4EBP1, according to a two-substrate reaction proceeding through  a random 
bi-bi mechanism (Cornish-Bowden, 2004; Demin and Goryanin, 2008):  
 
      
                   
                  
 (3) 
where 
 
         
    
      
    
   
     
 
  
     
 
   
     
  
 
 
2.3 Kinetic model of PTEN 
 
To model PTEN kinetics we used experimental data on PTEN activity, measured in 
unilamellar mixed phosphatidylcholine vesicles containing lipid substrate PIP3 (McConnachie 
et al., 2003). In this experiment bulk concentration of substrate PIP3 was varied at different 
fixed surface concentrations of PIP3, XPIP3 (mole fraction), in the vesicles. As a result,  the 
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dependence of PTEN activity with respect to hydrolysing of PIP3 on bulk concentration of PIP3 
at the different XPIP3 was obtained. To model these kinetic data, we used a MM rate equation: 
      
               
           
 (4) 
where  kPTEN and  KPIP3 are catalytic and Michaelis constants respectively and PIP3s= XPIP3PIP3. 
 
3. Results 
 
3.1. mTOR1 kinetic model parameterisation and validation through drug action  
 
To determine the kinetic parameters of Eqs. (1) and (2) we used in vitro experimental 
data on the phosphorylation of 4EBP1(Thr46) and S6K1(Thr389) by mTOR kinase (Tao et al., 
2010; Toral-Barza et al., 2005). Reproducing the experimental conditions of these in vitro 
experiments in our in silico model, we carried out the joint fitting of a set of experimental data 
including the dependencies of reaction rate V4EBP1 (Eq. (1)) on 4EBP1 concentration and also 
on ATP concentration at different concentrations of Rapamycin (Tao et al., 2010). 
Experimental data and the results of the fitting are shown in Figs. 5A and 5B. A set of obtained 
kinetic parameters along with the results of the bootstrap procedure (see Method) are given 
in Table 1. As a result of the bootstrap procedure, we obtained bootstrap samples of kinetic 
parameters and gave the median and the 95% percentile confidence interval for each 
parameters. The number of bootstrap samples in our calculations was 200 to ensure stable 
values of the medians and CIs. We also calculated the means and the standard normal 
confidence interval (see Methods) for the bootstrap samples and gave them in Table S1 in 
Supplement 6. Comparison of the means, medians, and CIs of the kinetics parameters 
obtained by two methods revealed similar results.  
According to modelling, mTOR kinase retains a fraction of its activity following 
Rapamycin inhibition due to its residual catalytic activity. Results of the fitting showed that 
mTOR1 retains 40% of catalytic activity at Rapamycin binding: the catalytic rate k4EBP1 is 
changed by the factor η4EBP1=0.42 μM CI(10
-3; 0.5) in the presence of Rapamycin (see the 
residual level of kinase activity in Fig. 5C and Table 1). The dissociation constant Kd,Rap2=6 nM 
CI(3.1; 6.9); obtained through fitting is close to the experimental value 12±4.2 nM and for the 
trimeric complex FKBP12-Rapamycin-FRB measured  by surface plasmon resonance (SPR) 
methods (Banaszynski et al., 2005). The value of the dissociation constant of ATP, Kd,ATP 
=8.4M CI(6.2; 8.9) obtained in our calculation, is substantially smaller than the value of the 
Michaelis constant  74 μM obtained in (Tao et al., 2010) based on the fitting of experimental 
data by the Michaelis-Menten equation (Fig. 5B). This discrepancy may be due to the facts 
that first we used a wider range of experimental data in the fitting procedure than used in 
(Tao et al., 2010) and second we defined the dissociation constant of ATP, Kd,ATP, in our model 
rather than the apparent Michaelis constant obtained in (Tao et al., 2010). 
 To validate the model with the obtained set of kinetic parameters we calculated the 
concentration dependence of mTOR1 activity (Eq. (1)) on Rapamycin concentration and found 
satisfactory agreement with the experimental dose dependence (Fig. 5C, line 1). We also 
calculated the dose dependence of mTOR1 activity on the concentration of BEZ235 (Fig. 5C, 
line 2). Comparison of the two dose dependencies for Rapamycin and BEZ235 shows that 
Rapamycin inhibits 60% of mTOR1 catalytic activity while BEZ235 suppresses activity totally 
(Fig. 5C). In this calculation, we determined the dissociation constant of BEZ235, Kd,BEZ, via the 
fitting of this single parameter of the model (Eq. (1)) against the experimental dose 
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dependence on reaction rate inhibition of truncated mTOR kinase (Tao et al., 2010). The 
obtained dissociation constant, Kd,BEZ=0.56 nM CI(0.48; 0.57), is close to the Michaelis 
constants Km=2.5 nM and 1.7 nM obtained based on the Michaelis-Menten equation fitting to 
radiometric and FRET assay data respectively (Tao et al., 2010) (Table 1). The obtained 
dissociation constant Kd,BEZ allows calculation of the IC50 value at the ATP concentration used 
in the experimental assay according to the following equation 
 
             
   
     
   (5) 
Eq. (5) follows from Eq. (1) and a definition of the IC50 value as the inhibitor concentration 
corresponding to a 50% inhibition of reaction rate V4EBP1 (derivation of Eq. (5) is given in 
Supplement 1). At concentration ATP=100 μM Eq. (5) gives IC50 = 8 μM that is close to the 
experimental value of IC50 = 10 nM obtained from the experimental dose dependence (Tao et 
al., 2010) (see experimental data in Fig. 5C). Accordingly, Eq. (5) parameterised with an ATP-
competitive mTOR1 inhibitor allows calculation of the IC50 values for BEZ235 at different ATP 
concentrations in an experimental assay and estimation of BEZ235 IC50 for different cells using 
a known ATP concentration. 
  In contrast to IC50 dependence (Eq. (5)) for the ATP-competitive inhibitor, the IC50 for 
the allosteric inhibitor Rapamycin does not depend on ATP concentration and according to Eq. 
(1) is equal to its dissociation constant: 
 
             (6) 
 
where       is either dissociation constant        or         depending the absence or 
presence of the FKBP12 protein in assays. This exact equality follows from the equation of 
reaction rate        Eq (1) (see derivation in Supplement 2). Comparison of the experimental 
IC50=9.6 nM (+FKBP12) and IC50>1 M (no FKBP12) with the theoretical values        =6 nM 
CI(3.1; 6.9) and        =1.7 μM CI(1.3; 1.8) confirms this relationship. 
To determine the kinetic parameters of mTOR1 related to the phosphorylation reaction 
of S6K1 kinase as described by Eq. (2) we used in vitro experimental data on the dependence 
of the reaction rate of S6K1(T389) phosphorylation on ATP concentration at different 
concentrations of LY294002 inhibitor (Toral-Barza et al., 2005). Given that LY294002 is a 
nonspecific inhibitor of PI3K (Vlahos et al., 1994), and considering the high homology in 
catalytic sites between PI3K and TOR kinases (Yang et al., 2013), we assumed that LY294002 
inhibits mTOR1 by a similar mechanism to PI3K (see mTOR1 catalytic cycle in Fig. 3). Results of 
the fitting are shown in Fig. 6A and kinetic parameters obtained are given in Tables 1 and S1. 
To demonstrate clearly that LY294002 is an ATP-competitive inhibitor of mTOR kinase, we also 
presented theoretical and experimental kinetic data in the Lineweaver-Burk plot in 
Supplement 3.  
To obtain the dissociation constants of Rapamycin binding to mTOR1, Kd,Rap1 and Kd,Rap2, 
we used the experimental dose dependence of the inhibition of S6K1(Thr389) phosphorylation 
reaction rate by Rapamycin (Toral-Barza et al., 2005). Given the derived kinetic parameters 
(Tables 1 and S1) and concentrations of species in the experimental assay (Toral-Barza et al., 
2005) we defined Kd,Rap1=1.7 μM CI(1.3; 1.8); and Kd,Rap2=1.6 nM CI(1.2; 1.7) in the absence and 
presence of FKBP12 respectively (Fig. 6B). The obtained values in the presence of FKBP12 are 
in agreement with nanomole values of dissociation constant: 0.35 nM and 12±0.8 nM 
obtained by fluorescence polarization assay (FPA) and SPR methods respectively (Banaszynski 
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et al., 2005). The experimental dissociation constant in the absence of FKBP12 is 490±39 nM 
and 26±0.8 μM obtained by FPA and SPR methods respectively (Banaszynski et al., 2005). Note 
that the values of dissociation constants of Rapamycin and mTOR kinase domain obtained in 
the model and those from experimental methods are close to the experimental values of 
IC50=2 nM in the presence of FKBP12 and IC50> 1 μM in the absence of FKBP12 in the 
experimental assay of S6K1(Thr389) phosphorylation (Toral-Barza et al., 2005), and these 
values conform to the relationship between Kd and IC50 values given by Eq. (6) for an allosteric 
inhibitor. 
To validate the mTOR1 model (Eq. (2)) with the parameter set (Table 1) we calculated 
the dose dependence of inhibition of S6K1(Thr389) phosphorylation by LY294002 (Fig. 6C), 
and compared the results with experimental data (Toral-Barza et al., 2005). In a similar 
manner to Eq. (5) the dependence of IC50 for LY294002 on ATP concentration is given by the 
equation  
 
             
   
     
   (7) 
 
which allows us to obtain the LY294002 IC50 value at the ATP concentration used in the 
experimental assay. At ATP concentration of 100 μM (Toral-Barza et al., 2005), Eq. (5) gives 
IC50=1.5 μM that corresponds to the experimental IC50 value obtained in this experiment (see 
experimental data in Fig. 6C). Accordingly, the satisfactory parameterisation of Eq. (7) for 
LY294002 may be used to calculate the LY294002 IC50 values at different concentrations of ATP 
in in vitro assays.   
We applied Eq. (7) to calculate the dose dependence of mTOR1 for LY294002 at 2 μM 
ATP and compared the obtained result with that calculated at 100 μM ATP (lines 1 and 2 in Fig. 
6C). As LY294002 is an ATP-competitive inhibitor of mTOR1, the IC50 decreases when ATP 
decreases (IC50=0.15 μM at 2 μM ATP).  Modelling showed that LY294002 becomes a stronger 
inhibitor of mTOR1 at low ATP concentrations in the range 1 μM - 10 μM, which corresponds 
to ATP concentration in mammalian cells (McLaughlin et al., 2002). Note, according to Eq. (6), 
the inhibition activity of the allosteric inhibitor Rapamycin does not depend on ATP 
concentration. To investigate synergistic effects of the combination of the allosteric inhibitor 
Rapamycin with the ATP-competitive inhibitor LY294002 we calculated the dose dependence 
of mTOR1 inhibition on LY294002 concentration at 10 nM Rapamycin and 100 μM ATP (line 3 
in Fig. 6C). The calculation revealed an additive effect of the two inhibitors and an increase of 
the LY294002 IC50 value from 1.5 μM to 30 μM when in combination with Rapamycin. Thus 
results do not indicate any synergistic effects of Rapamycin and LY294002 in combination. 
 
3.2 PI3K kinetic model parameterisation and validation through drug action 
 
The kinetic parameters of PI3K were derived by fitting of reaction rate VPI3K (Eq. (3)) 
against in vitro experimental data on the phosphorylation of PIP2 (Huang et al., 2011; Vlahos 
et al., 1994). Figs. 7A, B, and C show the results of fitting of the dependencies of the reaction 
rates on ATP and PIP2 concentrations in the absence and presence of LY294002 inhibitor. The 
form of the fitted Lineweaver-Burk plot confirms that LY294002 is an ATP-competitive 
inhibitor of PI3K (Fig. 7C). The obtained kinetic parameters of the kinase and dissociation 
constant of LY294002 are provided in Tables 2 and S2.  
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To estimate the dissociation constant of BEZ235 we applied the PI3K model to describe 
the dose dependence of ADP release on the inhibitor concentration for PI3K enzyme (Maira 
et al., 2008).  To reproduce experimental data (Maira et al., 2008), we modelled ADP 
production by an ordinary differential equation with the initial conditions corresponding to 
the experimental assay:  
    
  
         (8) 
where reaction rate VPI3K is defined by Eq. (3). The dissociation constant obtained as a result of 
best fitting of experimental dose dependence of ADP production on BEZ235 concentration 
(see Fig. 7D, line 1) is provided in Table 2 with experimental data on Ki and IC50 values for 
BEZ235 available from literature. We also used similar experimental data (Maira et al., 2008) 
to calculate the dose dependence for the LY294002 inhibitor. Comparison of the dose 
dependencies for BEZ235 and LY294002 is shown in Fig. 7D by lines 1 and 2 respectively. The 
dissociation constant Kd,LY=0.21 M CI(0.18; 0.24) obtained for the PI3K isoform as a result of 
the best fitting of experimental dose dependence is less than Kd,LY=0.6 M CI(0.3; 0.7) 
obtained above for bovine brain PI3K isolated in experimental work (Vlahos et al., 1994) (Table 
2). The obtained dissociation constant Kd,LY=0.21 M CI(0.18; 0.24) is close to the experimental 
dissociation constant Kd,LY =0.21±0.04 M for the PI3K isoform measured by the intrinsic 
tryptophan fluorescence method (Walker et al., 2000) (Table 2).  
To validate the calibrated model of PI3K (Eqs. (3) and (8)), we used the model to 
describe the experimental dependence of the IC50 value for BEZ235 and LY294002 on ATP 
concentration measured for dose dependence of ADP production for a PI3K enzyme assay 
(Maira et al., 2008). The theoretical ATP dependence of the IC50 values for BEZ235 and 
LY294002 was obtained based on the analytical solution of Eq. (8). As a solution of Eq. (8) 
cannot be written explicitly we expressed the dependence of the IC50  value on the initial ATP 
concentration      in the form  
         
 
 
    
     
    
      
    
 
    
     
    
  
  
 
 
 
  
 
 
(9) 
where 
  
               
            
   
    
      
 
  
                                          
 
Here                   is the final concentration of ATP at the reaction terminal time 
   in the absence of inhibitors which can be defined from Eq. (8). The detailed derivation of 
Eq. (9) is given in Supplement 4. The obtained Eq. (9) allows calculating dependence of the 
     value on the initial concentration      based on the solution of Eq. (8)             
                 in the absence of inhibitors. Note, using of this equation does not 
require calculation of dose dependence for the inhibitor at the different concentrations of ATP 
and numerical estimation of the      values. The dependencies of the      value for BEZ235 
and LY294002 on      concentration were calculated based on Eq. (9) with kinetic 
parameters obtained in the fitting procedure (Table 2) and the initial concentrations of the 
substrates corresponding to the experimental conditions in the assay (Maira et al., 2008). 
Dissociation constants for BEZ235 and LY294002 in these calculations were         nM and 
          M which lie within the obtained CIs of these parameters (Tables 2 and S2). 
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In Fig. 8A, we compared the obtained theoretical dependencies of the IC50 with 
experimental data (Maira et al., 2008). The linear dependence of the IC50 values on      
concentration obtained in the model corresponds to the ATP-competitive mechanism for 
BEZ235 and LY294002 inhibitors (Fig. 8A and 8B respectively) and satisfactorily describes the 
observed experimental dependencies of the IC50 values for these inhibitors (Maira et al., 
2008).  To investigate the value where the line intercepts the IC50-axis, we plotted the linear 
dependence of the IC50 values on ATP concentration (dotted lines in Figs. 8A and 8B) obtained 
based on the dose dependence of the reaction rate       on the inhibitor concentration (Eqs. 
(5) and (7)).  Exact coincidence between two lines shows equivalence of the IC50 measurement 
in both in vitro assays at the specific experimental conditions. Therefore, the intercept of the 
regression line may serve as an estimate of dissociation coefficients of ATP-competitive 
inhibitors. The intercepts for the LY294002 and BEZ235 IC50s gave the estimates for 
        nM and           M respectively that satisfactorily agrees with the fitted values 
of these dissociation constants (Table 2). Thus experimental data on the dependence of IC50 
on ATP concentration for ATP-competitive inhibitors can be used to estimate dissociation 
constants of the inhibitors. 
 
 
3.3 PTEN kinetic model parameterisation  
 
Fig. 9 (lines) shows the fitting of the reaction rate VPTEN (Eq. (4)) depending on PIP3 
concentration at four surface concentrations of PIP3, XPIP3 (mole fraction), against 
experimental data (McConnachie et al., 2003). As a result of fitting, a low value of the 
Michaelis constant was obtained, KPIP3=29  nM (20; 31) nM (Tables 3 and S3). Plotting 
theoretical and experimental data in the reciprocal axes, 1/PIP3 and 1/VPTEN, showed that the 
rate equation in the form (Eq. (8)) describes satisfactorily the kinetic behaviour of VPTEN at 
different XPIP3. Moreover the straight lines corresponding to different XPIP3 intersect the 1/VPTEN 
axis at the same point, which means that maximum rate of PTEN is independent of XPIP3, and 
the reaction rate VPTEN  depends on the concentration of PIP3 in the membrane (XPIP3 PIP3) 
according to Eq. (4). 
 
Discussion 
 
The results of our kinetic modelling of PI3K, mTOR1 kinases and PTEN phosphatase 
showed that in vitro kinetics of these purified proteins can be described satisfactorily with 
Michaelis-Menten approximation, i.e. with a fast substrate binding approximation. The 
obtained kinetic parameters of these proteins are partly in agreement with those obtained 
previously by the fitting of MM equations against separate kinetic curves (Maira et al., 2008; 
Tao et al., 2010; Toral-Barza et al., 2005). In line with the schematic in Fig. 2 we enhanced the 
estimation of a number of kinetic parameters of PI3K and mTOR1 kinases through the 
application of two-substrate reaction rate equations calibrated against experimental data 
describing kinetics in different experimental conditions. This calibration approach allowed us 
to estimate dissociation constants of the substrates instead of apparent Michaelis constants 
that depend on experimental assay conditions such as the second substrate concentration in 
two-substrate reactions. The developed models were then applied to describe allosteric 
inhibition of mTOR kinase by Rapamycin and ATP-competitive inhibition of PI3K and mTOR 
kinases by LY294002 and BEZ235.  
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Modelling of the mTOR kinase showed high selectivity of allosteric inhibitor Rapamycin 
to mTOR1 substrates: Rapamycin differentially regulates mTOR1 activity relating to its 
substrates S6K1 and 4EBP1. In the model, Rapamycin changes the catalytic rate of 4EBP1 
phosphorylation k4EBP1 by a factor of 4EBP1=0.4 (Fig. 5C and Table 1). Analysis of the kinetic 
data and dose dependence showed that mTOR1 retains 40% of catalytic activity without a 
change in dissociation constant to the substrate, Kd,4EBP1 (Fig. 5). In contrast, Rapamycin both 
alone and in a complex with FKBP12 inhibits completely the catalytic activity of mTOR1 
relating to S6K1 phosphorylation (S6K1=0). In agreement with experimental data, the 
modelling showed that Rapamycin completely inhibits S6K1 phosphorylation at a Rapamycin 
concentration greater than 0.1 M and 100 M in the presence and absence of FKBP12 
respectively (Shor et al., 2008)  (Fig. 6D).  
Experimental investigations into the crystal structure of a truncated mTOR kinase (Yang 
et al., 2013) suggest that the binding of Rapamycin-FKBP12 complex near the mTOR substrate-
binding site inhibits kinase activity due to restricting the accessibility of the substrates to the 
recessed catalytic cleft. As per the schematic in Fig. 2, we can integrate this knowledge into 
the model. According to our modelling, the Rapamycin-FKBP12 complex does not compete 
with mTOR1 substrates and it binds to mTOR1 jointly with either 4EBP1 or S6K1 kinases and 
forms triple complexes in the form Rapamycin-FKBP1-mTOR-Substrate as depicted in the 
scheme of the mTOR catalytic cycle (Fig. 3). In the model, Rapamycin decreases the mTOR1 
catalytic rate relating to 4EBP1 and S6K1 without impacting mTOR1 affinity to substrates 
(Table 1). This decrease in catalytic rate may result from the observation that the Rapamycin-
FKBP12 complex perturbs the positioning of the substrate at the catalytic site but does not 
influence significantly substrate binding. We suggest that the observed differences in catalytic 
rate is responsible for Rapamycin selectivity to mTOR1 substrates and this property might be 
due to steric effect stemming from the different sizes of S6K1 and 4EBP1 proteins: 60 KDa and 
18 KDa respectively. Thus the active site restriction mechanism proposed in (Yang et al., 2013) 
corresponds to the negative regulation mechanism of catalytic rate in our model.  
 Yang et al. (Yang et al., 2013) propose a biparticle substrate-recruitment mechanism 
for S6K1 binding to the mTOR active site, according to which the FRB provides a secondary 
binding site for the substrate near the entrance to the catalytic cleft. They suggest that this 
Rapamycin-binding site participates in substrate binding with the recessed active site of 
mTOR. In our kinetic modelling, Rapamycin both alone and in a complex with FKBP12 does not 
change the dissociation constants of either substrate 4EBP1 or S6K1, and only influences the 
catalytic rate of the enzyme. Accordingly, we suggest that either: 1) our analysis of kinetic data 
is not sensitive to the biparticle substrate-recruitment mechanism suggested in (Yang et al., 
2013); or 2) the Rapamycin-binding site interacts with other parts of mTOR, which changes the 
catalytic rate of the enzyme and defines an allosteric inhibition mechanism (Choo et al., 2008; 
Yang et al., 2013). An allosteric mechanism of mTOR1 inhibition by Rapamycin is supported by 
modelling kinetic data on the dependence of 4EBP1 phosphorylation reaction rate on ATP 
concentration at different concentrations of Rapamycin (Tao et al., 2010), which shows 
inhibition of the catalytic rate  without changing substrate affinity (Fig. 5A).  
In the model, the FKPB12 protein enhances affinity of Rapamycin to the FRB domain of 
mTOR and does not influence substrate affinity. Note our modelling showed that the 
dissociation constant of complex Rapamycin-FKBP1 Kd,Rap2 differs for the substrates 4EBP1 and 
S6K1 (7±1.1 nM and 1.5±0.5 nM respectively) and these values correlate with their 
experimental IC50 values (9.6 nM and 2 nM respectively, Table 1). This difference may indicate 
steric interaction between Rapamycin-FKBP12 complex and the substrates in the model.  A 
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high affinity of Rapamycin-FKBP12 complex to the mTOR1-S6K1 complex contributes to higher 
inhibition of S6K1 in comparison with 4EBP1. Note, the calculation revealed high selectivity of 
mTOR1 to its substrates 4EBP1 and S6K1 (10.3±2 μM and 0.4±0.2 μM respectively). 
Additionally, mTOR1 was reported to show high selectivity to S6K isomers, S6K1 and S6K2, 
expressing differently in specific cells (So et al., 2016). 
To juxtapose in vitro kinetic data for purified enzymes and in vivo data for cell culture we 
compared modelling results and experimental data on inhibition of cancer cell population by 
Rapamycin (Brachmann et al., 2009). Residual activity of mTOR1 (40%) relating to 4EBP1 
phosphorylation obtained in the modelling correlates with survival dose dependence for a set 
of breast cancer cell lines treated by Everolimus (a derivative of Rapamycin) for (residual 
activity is 50%) (Brachmann et al., 2009). This fact suggests that inhibition of 4EBP1 exerts 
primary effect on cancer cell proliferation in comparison with S6K1 inactivation (So et al., 
2016). 
While a Michaelis-Menten approximation may satisfactorily describe the main features 
of mTOR kinetics, many kinetic properties lie out with the descriptive power of the MM 
approach. For example, whilst modulation of the mTOR1 activity by Rapamycin is described 
satisfactorily based on the kinetic properties of mTOR kinase, the inhibition of mTORC2 
complex is not incompatible with the MM approximation: Rapamycin does not inhibit mTOR2 
in the nanomolar concentration range (Yang et al., 2013) and a reduction in mTOR2 activity is 
only observed upon prolonged incubation with nanomolar rapamycin (Sarbassov et al., 2006). 
The mechanisms underlying this difference are presumably due to the different structural 
components of mTOR1 and mTOR2 complexes, including the fact that FKBP12-Rapamycin 
binds with a de novo assembled mTOR2 complex that hinders binding of Rictor components to 
the mTOR2 complex (Shor et al., 2008; Yang et al., 2013).  
Our model does explain the Rapamycin selectivity to mTOR1 substrates S6K1 and 4EBP1 
at the enzymatic level, but it is problematic to translate this on-target mechanism to in vivo 
data: Rapamycin was reported to inhibit S6K1 kinase in all cell lines that were tested, while the 
phosphorylation inhibition of 4EBP1 depends on cell type (Choo et al., 2008). Moreover in 
many cell types recovery from the initial inhibition of 4EBP1 was observed within 6 hours and 
was followed by its hyper-phosphorylation, which causes a recovery in cap-dependent 
translation despite continued S6K1 inhibition as a result of Rapamycin treatment (Choo et al., 
2008). A further anomaly of mTOR kinase behaviour observed in vivo is that phospho-sites 
4EBP1(T37/46), which are direct targets of mTOR kinases in vitro, are not Rapamycin sensitive 
in vivo, yet T389 on S6K1 is Rapamycin sensitive in vitro and in vivo (Choo et al., 2008).   
The developed model of mTOR kinase was applied to describe the action of ATP-
competitive inhibitors LY294002 and BEZ235. The dissociation constants Kd obtained in the 
calculation were significantly smaller than the IC50 values observed in in vitro experiments (Tao 
et al., 2010). To explain this difference, we used the dependence of the IC50 value for ATP-
competitive inhibitor on ATP concentration, derived in the MM approximation. This 
dependence of the IC50 values for BEZ235 and LY294002 (Eqs. (5) and (7) respectively) 
describes well the observed difference between the Kd and IC50 values. The obtained 
dependence can be used to calculate the IC50 values for these inhibitors for different 
experimental assays and for the estimation of IC50 in in vitro experiments in cells with different 
ATP levels. These relations can be also used in the analysis of variation in the IC50 values for 
LY294002 and BEZ235 inhibitors in cancer lines characterizing by different ATP levels (Moreno-
Sánchez et al., 2014; Zhou et al., 2012). 
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Note that according to the model of mTOR1 kinase (Eqs. (1) and (2)) and general 
properties of MM approximation (Brandt et al., 1987; Yung-Chi and Prusoff, 1973) the IC50 
value for allosteric inhibitor Rapamycin does not depend on ATP concentration and its IC50 is 
equal to the dissociation constant of Rapamycin Kd,Rap in relation to Eq. (6). This result is in 
agreement with experimental IC50 values (2 nM and 7 nM for S6K1 and 4EBP1 respectively) 
which are close to theoretical dissociation constants Kd,Rap =1.5±0.5  nM and 7±1.1  nM 
respectively (Table 1). A comparison of dose dependencies for treatment of different cancer 
cell lines by rapalog, RAD001, showed that the lethal dose, LD50  10 nM (Santiskulvong et al., 
2011), is almost independent of cell lines sensitive to RAD001 and satisfactorily correlates with 
the dissociation constant and IC50 values obtained in the modelling.  
To investigate the joint effect of allosteric and ATP-competitive inhibitors on the mTOR 
kinase activity we calculated mTOR inhibition by the combination of Rapamycin and LY294002. 
The result showed an additive and not a synergistic effect of this combination. Experimental 
data showed that a combination of Rapamycin and LY294002 suppresses AKT phosphorylation 
but without significant effect on treatment efficacy (Werzowa et al., 2009).  
PTEN kinetics were modelled based on experimental data on PTEN activity measured in 
phosphatidylcholine vesicles at different molar fractions of PIP3 (McConnachie et al., 2003). 
We modelled PIP3 phosphatase activity of PTEN by a Michaelis-Menten equation that 
considered PIP3 fraction in mixed lipid vesicles. Our model is simpler than the three-
parameter model used in (McConnachie et al., 2003) to describe the hopping/scooting 
mechanism of PTEN catalysis (see Michaelis-Menten-like equation in Table 3). In this model, 
the maximum reaction rate depends on the surface fraction of PIP3 in the vesicle membrane, 
and the rate equation takes into account non-specific binding of PTEN to the membrane 
surface with low affinity, KS =84 mM (McConnachie et al., 2003). In our model we showed that 
experimental PTEN kinetics might be satisfactory described in Michaelis-Menten 
approximation where the maximum reaction rate does not depend on molar fraction of PIP3 
in the membrane and that the reaction occurs through the formation of Michaelis-Menten 
enzyme-substrate complex without non-specific binding of PTEN to the membrane. Our model 
gave a low Michaelis constant KPIP3=43 nM that suggests that PTEN is highly sensitive to low 
concentrations of PIP3 lipids produced in the plasma membrane during PI3K activation 
(Maehama et al., 2001).  
Here, our modelling and obtained results show that integrated analysis of experimental 
data on enzymatic kinetics, enzyme activity following drug action, and enzyme molecular 
structure gives mutually complementary information on regulation mechanisms of catalysis 
and mechanisms of inhibitor action in various experimental conditions. Our framework 
provides an approach to integrate protein and drug data into a unified, validated kinetic 
model that may be used to predict drug efficacy in a range of cellular conditions.  
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Figure legends  
 
Fig. 1. Scheme of PI3K/PTEN/AKT/mTOR1 pathway activated by growth factor (GF) and 
inhibited by allosteric inhibitor, Rapamycin, and ATP-competitive inhibitors BEZ235 and 
LY294002. 
 
Fig. 2. Systems biology approach to kinetic model design, discrimination, and calibration: 
incorporation and fitting of in vitro data obtained under different experimental conditions. 
Application of the model to the prediction of IC50 values for drugs in different in vitro and in 
vivo conditions. 
 
Fig. 3. Catalytic cycle of mTOR1 complex catalysing the reactions of S6K1 and 4EBP1 
phosphorylation in the presence of ATP-competitive inhibitors (Inh) either BEZ235 or LY294002 
and allosteric inhibitor Rapamycin (Rap).  
 
Fig. 4. Catalytic cycle of PI3K in the presence of ATP-competitive inhibitors, BEZ235 and 
LY294002.  
 
Fig. 5. (A): Reaction rate of 4EBP1(Thr46) phosphorylation catalysed by mTOR kinase  
depending on ATP concentration at different concentrations of Rapamycin. Lines - theoretical 
results: line 1 - 0 nM, line 2 – 8 nM, line 3 – 20 nM, line 4 – 128 nM. Points - experimental data: 
200 nM 4EBP1, 3 nM truncated mammalian mTOR kinase, 200 nM FKBP12 protein in TR-FRET 
assay (Tao et al., 2010). (B): Reaction rate of 4EBP1(Thr46) phosphorylation catalysed by mTOR 
kinase depending on 4EBP1 concentration. Line - theoretical result. Points - experimental data: 
300 μM ATP, 6.7 nM truncated mammalian mTOR kinase in radiometric filtration assay (Tao et 
al., 2010). (C): Dose dependence of mTOR1 reaction rate inhibition by Rapamycin (line 1) and 
BEZ235 (line 2). Lines – theoretical results. Points - experimental data: 40 μM 4EBP1, 20 nM 
mammalian mTOR1, and 100 μM ATP in radiometric filtration assay (Tao et al., 2010).      
 
Fig. 6.   (A): Dependence of mTOR1 reaction rate of S6K1(Thr389) phosphorylation on ATP 
concentration at different concentrations of LY294002 inhibitor. Lines - theoretical results:  line 
1 - 0 μM, line 2 - 0.8 μM, line 3 - 1.6 μM, and line 4 - 3.2 μM LY294002. Points - experimental 
data:  1.25 μM S6K1, ATP 100 μM, 6 nM FLAG-TOR in the assay (Toral-Barza et al., 2005).  (B): 
Dose dependence of mTOR kinase reaction rate of S6K1(Thr389) phosphorylation on  
Rapamycin concentration in the presence (line 1) and absence of FKBP12  (line 2). Lines -
theoretical results. Points - experimental data: circles and triangles (Toral-Barza et al., 2005), 
squares (Shor et al., 2008). Experimental conditions: 1.25 μM S6K1, 6 nM FLAG-TOR, and 100 
μM ATP in the assay. (C): Dose dependence of inhibition of FLAG-TOR(3.5) reaction rate of 
S6K1(Thr389) phosphorylation by LY294002. Lines 1 and 2 - theoretical calculation at 100 μM 
and 2 μM ATP, respectively. Points - experimental data:  1.25 μM S6K1, 100 μM ATP, 6 nM 
FLAG-TOR(3.5) in the assay (Toral-Barza et al., 2005).  Line 3 - computational dose dependence 
of inhibition of mTOR kinase by combination of LY294002 and  Rapamycin (10 nM) at 100 μM 
ATP. 
 
Fig. 7.  (A): The dependence of PI3K reaction rate on ATP concentration.  Line – theoretical 
result. Points - experimental data:  2 μM PIP2 in the assay (Huang et al., 2011). (B): The dose 
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dependence of PI3K reaction rate on PIP2 concentration. Line – theoretical result. Points - 
experimental data:  2 mM ATP in the assay (Huang et al., 2011). (C): Lineweaver-Burk plot of 
PI3K reaction rate for different LY294002 concentrations: line 1 - 0 μM, line 2 - 1 μM, line 3 - 
5μM, line 4 - 10 μM, and line 5 - 20 μM LY294002. Lines – theoretical results. Points - 
experimental data: 400 μM PIP2 in the assay (Vlahos et al., 1994). (D): Dose dependence of 
ADP production inhibition on BEZ235 (line 1) and LY294002 (line 2) concentrations. Lines - 
theoretical calculations, points - experimental data on the inhibition of ADP production by 
PI3Kα (p85/p110α complex) on BEZ235 (circles) and LY294002 (squares) concentrations: 0.5 
μATP, 10 μM PIP2, 0.4 μg/mL PI3Kα, time of reaction stopping t=60 min in the ADP-release 
assay (Maira et al., 2008).   
 
Fig. 8. Dependencies of IC50 for BEZ235 (A) and LY294002 (B) for PI3K on ATP concentration 
obtained based on dose dependence of ADP production on inhibitor concentration. Lines – 
theoretical  IC50 dependencies for ADP production calculated according to Eq. (9) (solid lines) 
and for the reaction rates according to Eqs. (5) and (7) (dotted lines). Points - experimental 
data for PI3K: 10 μM PIP2, 10 nM PI3Kα in the assay, reaction was terminated  after tm=120 
min (Maira et al., 2008). 
 
Fig. 9. Dependence of reaction rate of PIP3 hydrolysis by PTEN on PIP3 concentration  at the 
different molar fractions of PIP3, X
PIP3
 given in reciprocal axes 1/V
PTEN
 and 1/PIP3. Lines - 
theoretical results, points - experimental data on PTEN activity measured in phosphatidilcholin 
vesicles at X
PIP3
=0.1 (filled circle, line 1), 0.01 (open circles, line 2), 0.002 (filled squares, line 3), 
and 0.001 (open squares, line 4) (McConnachie et al., 2003). 
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Table 1. Comparison of the obtained kinetic parameters of mTOR1 and its inhibitors, 
Rapamycin, BEZ235, and LY294002 with in vitro experimental data. Km and Ki are Michaelis 
and inhibition constants respectively. The median and the 95% percentile confidence interval 
(in brackets) obtained in the bootstrap process are given for the parameter values.  
 
Fitted values of the kinetic parameters References 
Reaction rate, k4EBP1  
0.47 min-1 (0.41; 0.48) 0.47 min-1 (Tao et al., 2010) 
Dissociation constant of ATP,  Kd,ATP  
8.4  μM (6.2; 8.9)  Km= 74 μM  (Tao et al., 2010)     
Dissociation constant of 4EBP1, Kd,4EBP1  
11.1 μM (7.8; 11.8) Km=9.5 μM  (Tao et al., 2010)     
Dissociation constant of S6K1, Kd,S6K1  
0.42 μM (10-3; 0.5) Km=0.8 μM (Tao et al., 2010)  
Inhibition coefficient of mTOR reaction rate for  
4EBP1 phosphorylation by Rapamycin, ηRap 
0.43 (0.38; 0.44)   
Dissociation constant of Rapamycin-mTOR, Kd,Rap1 
1.7 μM (1.3; 1.8); no FKBP12 and +S6K1 IC50> 1  μM  (Toral-Barza et al., 2005) 
 Kd=490±39 nM
1), FPA (Banaszynski et al., 2005) 
 Kd=26 ± 0.8 nM
1), SPR (Banaszynski et al., 2005)  
Dissociation constant of Rapamycin-mTOR, Kd,Rap2 
6 nM (3.1; 6.9); +FKBP12 and +4EBP1  IC50=9.6 nM  (Tao et al., 2010)  
 Kd=0.35 nM
2), FPA (Banaszynski et al., 2005) 
 Kd=12±4.2 nM
2), SPR (Banaszynski et al., 2005)  
 Kd=3 nM
2) (Chen et al., 1995) 
1.6 nM (1.2; 1.7);  +FKBP12 and  +S6K1  IC50=2 nM  (Toral-Barza et al., 2005) 
Dissociation constant of BEZ235, Kd,BEZ 
0.56  nM  (0.48; 0.57)       Ki =2.5 nM, 1.7 nM  (Tao et al., 2010)     
 IC50=10 nM    (Tao et al., 2010)     
Dissociation constant of LY294002, Kd,LY   
0.12  μM (0.09; 0.13)           IC50=1.5 μM  (Tao et al., 2010) 
1) Experimental dissociation constants  of Rapamycin-mTOR complex in the absence of 
FKBP12 protein obtained in Fluorescence polarization assays (FPA) and by Surface 
Plasmon Resonance (SPR) methods.
 
2) Experimental dissociation constants of Rapamycin-mTOR complex in the presence of 
FKBP12 protein.
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Table 2. Kinetic parameters of PI3K and its inhibitors, BEZ235 and LY294002 obtained as the 
result of experimental data fitting.  The median and the 95% percentile confidence interval (in 
brackets) obtained in the bootstrap process are given for the parameter values.  
 
 
Fitted values of the kinetic parameters References 
Maximum rate of the reaction, Vmax 
160 pmol/g/min  (54; 200)  
Dissociation constant of ATP,  Kd,ATP 
30.3  μM (27.1; 85.1) Km= 24±4.2 μM  (Huang et al., 2011)    
Dissociation constant of PIP2, Kd,PIP2 
70.3  μM  (27.1; 85.1)    Km=68.7±5.2 μM  (Huang et al., 2011)    
Dissociation constant of LY294002, Kd,LY 
0.6  μM  (0.3; 0.7)     
0.21 μM1) (0.18; 0.24), (p85/p110α) 
0.19 μM2) (0.16; 0.22), (p85/p110α) 
Ki=1.6 μM (Vlahos et al., 1994) 
IC50=1.43 μM p85/p110α (Huang et al., 2011) 
IC50=1 μM p85/p110α (Maira et al., 2008) 
IC50=0.186 μM  p110α (Gharbi et al., 2007)    
Kd,LY=0.21±0.04 μM, PI3K (Walker et al., 2000) 
Dissociation constant of BEZ235, Kd,BEZ       
1.6 nM3) (1.2; 2.1) 
(p85/p110α) 
0.50 nM4) (0.45; 0.51) 
(p85/p110α) 
IC50=5±4 nM, p110 (Maira et al., 2008) 
IC50=4±2 nM, p110α (Maira et al., 2008) 
IC50=75±45 nM, p110 (Maira et al., 2008) 
IC50=7±6 nM, p110 (Maira et al., 2008) 
 
1),3) 
This estimate was obtained at the fitting of experimental dose dependence measured in the 
MaxiSorp
TM
 assay, Fig. S1 B in (Maira et al., 2008).  
2),4) 
This value was obtained based on experimental dose dependence in the ADP-release assay, 
Fig. S1 A in (Maira et al., 2008). 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
33 
 
Table 3. Kinetic parameters of PTEN. The median and the percentile confidence interval (in 
brackets) obtained in the bootstrap process are given for the parameter values.   
 
Parameters Fitted values References 
kc 48 min
-1 (41; 49)  kc =73±4.4  min
-1   (McConnachie et al., 2003) 
  kc =120  min
-1   (Maehama et al., 2001) 
KPIP3 29  nM (20; 31)      Km < 50 μM (Maehama et al., 2001)    
  ikm=0.04±0.005
1 (mol%) (McConnachie et al., 
2003) 
  KS =84±9.0
1 mM (McConnachie et al., 2003) 
1Parameters of the following equation (McConnachie et al., 2003) 
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